Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2017 Summary Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 36 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Ophthalmology, Toxicology, Infectious Disease, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Psoriasis, Friedreich Ataxia, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Cardiomyopathy, Chagas Disease (American Trypanosomiasis), Chronic Obstructive Pulmonary Disease (COPD), Diabetic Complications, Diabetic Nephropathy, Medulloblastoma, Neuroblastoma, Radiodermatitis, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Atherosclerosis, Breast Cancer, Cardiovascular Disease, Cerebral Vasospasm, Chronic Kidney Disease (Chronic Renal Failure), Corneal Degeneration, Encephalomyelitis, Huntington Disease, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Metastatic Breast Cancer, Metastatic Melanoma, Mitochondrial Diseases, Neuro Muscular Disorders, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Radiation Injury, Relapsing Remitting Multiple Sclerosis (RRMS), Retinal Degeneration, Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis. The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects - The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Overview Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development Arbor Pharmaceuticals LLC Bayer AG BioApex sro Biogen Inc C4X Discovery Holdings PLC Catabasis Pharmaceuticals Inc Daiichi Sankyo Company Ltd Evgen Pharma Plc Ixchel Pharma LLC Jiangsu Hengrui Medicine Co Ltd Mochida Pharmaceutical Co Ltd Reata Pharmaceuticals Inc Rigel Pharmaceuticals Inc vTv Therapeutics Inc Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles BA-1521 - Drug Profile Product Description Mechanism Of Action R&D Progress bardoxolone methyl - Drug Profile Product Description Mechanism Of Action R&D Progress CAT-4001 - Drug Profile Product Description Mechanism Of Action R&D Progress DH-404 - Drug Profile Product Description Mechanism Of Action R&D Progress dimethyl fumarate DR - Drug Profile Product Description Mechanism Of Action R&D Progress IXC-103 - Drug Profile Product Description Mechanism Of Action R&D Progress IXC-105 - Drug Profile Product Description Mechanism Of Action R&D Progress LH-503 - Drug Profile Product Description Mechanism Of Action R&D Progress LH-526 - Drug Profile Product Description Mechanism Of Action R&D Progress MG-132 - Drug Profile Product Description Mechanism Of Action R&D Progress MIND-4 - Drug Profile Product Description Mechanism Of Action R&D Progress monosodium luminol - Drug Profile Product Description Mechanism Of Action R&D Progress nifurtimox - Drug Profile Product Description Mechanism Of Action R&D Progress nifurtimox SR - Drug Profile Product Description Mechanism Of Action R&D Progress omaveloxolone - Drug Profile Product Description Mechanism Of Action R&D Progress R-970 - Drug Profile Product Description Mechanism Of Action R&D Progress RS-9 - Drug Profile Product Description Mechanism Of Action R&D Progress RTI-79 - Drug Profile Product Description Mechanism Of Action R&D Progress SFX-01 - Drug Profile Product Description Mechanism Of Action R&D Progress SFX-02 - Drug Profile Product Description Mechanism Of Action R&D Progress SFX-03 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate Nrf2 for Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate Nrf2 for Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target NRF2 and BACH1 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate NRF-2 for COPD - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit GSK3B and Activate Nrf2 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress TBE-31 - Drug Profile Product Description Mechanism Of Action R&D Progress TFM-735 - Drug Profile Product Description Mechanism Of Action R&D Progress trigonelline hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress VCB-101 - Drug Profile Product Description Mechanism Of Action R&D Progress VCB-102 - Drug Profile Product Description Mechanism Of Action R&D Progress VEDA-1209 - Drug Profile Product Description Mechanism Of Action R&D Progress XP-23829 - Drug Profile Product Description Mechanism Of Action R&D Progress Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Products Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Product Development Milestones Featured News & Press Releases Jun 01, 2017: Reata Pharmaceuticals Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich's Ataxia Apr 24, 2017: TECFIDERA Data Demonstrates Improved Outcomes with Early MS Treatment at American Academy of Neurology in Boston Apr 18, 2017: Biogen Highlights Data on TECFIDERA at AAN Congress Mar 31, 2017: Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Mar 28, 2017: Evgen Pharma: Further US Patent Grant Feb 23, 2017: Reata Announces Initiation of Phase 2/3 Study of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome Feb 14, 2017: Evgen Pharma Announces Patent Grant in the United States Feb 13, 2017: Evgen Pharma Announces Services Agreement with Drug Development Consortium Jan 17, 2017: Evgen Pharma Announces First Patient Dosed in Phase II Breast Cancer Trial Jan 11, 2017: Evgen Pharma Receives Positive DSMB Review of SAS Trial Nov 29, 2016: Hardman Research: Clinical potential of sulforaphane Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-4001 at Investor Day Nov 16, 2016: New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson's Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego Nov 15, 2016: Bayer to Fight Chagas Disease in Children Nov 14, 2016: Reata Announces Plan for Global Phase 2/3 Trial in Chronic Kidney Disease Caused by Alport Syndrome Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Arbor Pharmaceuticals LLC, H1 2017 Pipeline by Bayer AG, H1 2017 Pipeline by BioApex sro, H1 2017 Pipeline by Biogen Inc, H1 2017 Pipeline by C4X Discovery Holdings PLC, H1 2017 Pipeline by Catabasis Pharmaceuticals Inc, H1 2017 Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Pipeline by Evgen Pharma Plc, H1 2017 Pipeline by Ixchel Pharma LLC, H1 2017 Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Pipeline by Mochida Pharmaceutical Co Ltd, H1 2017 Pipeline by Reata Pharmaceuticals Inc, H1 2017 Pipeline by Rigel Pharmaceuticals Inc, H1 2017 Pipeline by vTv Therapeutics Inc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Dormant Products, H1 2017 (Contd..2), H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
